Biotechnology

AMOYTOP

AMOYTOP released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 797.79 M (forecast CNY 893 M), actual EPS CNY 0.4

AMOYTOP to Release FY2026 Q1 Earnings on April 29 After-Market (BJT), Forecast Revenue CNY 893 M

AMOYTOP to Release FY2025 Annual Earnings on March 27, Pre-Market (BJT), Forecast Revenue CNY 3.656B, EPS CNY 2.59

AMOYTOP released FY2025 Q4 earnings on February 10 Pre-Market (BJT), actual revenue CNY 1.216 B (forecast CNY 1.14 B), actual EPS CNY 0.8727

AMOYTOP released FY2025 annual earnings on February 10 Pre-Market BJT, actual revenue CNY 3.696 B (forecast CNY 3.656 B), actual EPS CNY 2.52 (forecast CNY 2.59)

AMOYTOP released FY2025 Q3 earnings on October 22 After-Market (BJT), actual revenue CNY 968.93 M (forecast CNY 1.011 B), actual EPS CNY 0.5904

AMOYTOP released FY2025 9 Months Earnings on October 22 After-Market (BJT), with actual revenue of CNY 2.48 B and EPS of CNY 1.6394

AMOYTOP to Release FY2025 Q3 Earnings on October 23 After-Market (BJT), Forecast Revenue CNY 1.011 B

AMOYTOP released FY2025 Q2 earnings on August 20 After-Market BJT, actual revenue CNY 837.27 M (forecast CNY 811 M), actual EPS CNY 0.5989

AMOYTOP released FY2025 Semi-Annual earnings on August 20 After-Market (BJT), actual revenue CNY 1.511 B, actual EPS CNY 1.05

AMOYTOP FY2025 Semi-Annual Earnings Release on August 21, 2025 (BJT)

Tebo Bio Accepts Institutional Research on Long-Acting Growth Hormone Strategies

Guokin Securities Gives 'Buy' Rating to Tobio Biologics

TPB confirms sales milestone with Jiutian Bio for innovative drugs

Xiamen Tebop Biopharm Submits New Trademark Applications and Increases R&D Investment

TBioPharm and Aligos Collaborate on Chronic Hepatitis B Clinical Trial

Tebo Biotech's Yipei Growth Hormone Injection Approved for Market

Tibet Trust Reduced 8.2375 million Shares of Tebo Bio

TBio's Profitability Continues to Improve

TBio's Q1 Non-Net Profit Growth Slows Down

ARKG

688278

Aligos reported $2.186 million in revenue for 2025, a 39% decrease from the previous year, primarily due to the end of a collaboration with Amoytop and changes following a Merck agreement. The net loss improved to $(24.193) million, with a loss per share of $(2.45). A $60.184 million unrealized gain from common warrants helped reduce pre-tax losses. The company expects cash to fund operations into Q3 2026 but will need additional capital to sustain R&D programs. Key pipeline advancements include progress in clinical studies for pevifoscorvir sodium and ALG-055009.

TradingView

VG Health

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

iShares Biotechnology ETF

iShares Global Healthcare

Merck

First Trust NYSE Arca Biotech Index Fd

Aligos Therapeutics

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Aligos 10-K: Revenue $2.19M, EPS (2.45) — 2025 Annual Filing

002466

09696

As of January 2026, Asian markets are facing mixed performances, particularly in China and Japan. Investors are focusing on undervalued stocks based on intrinsic valuation estimates. Notable picks include Zhejiang Century Huatong Group, Xiamen Amoytop Biotech, and WuXi XDC Cayman, all showing significant discounts to their fair values. Morimatsu International Holdings and Tianqi Lithium are highlighted for their growth potential despite recent challenges. The article emphasizes the importance of thorough analysis and offers insights into various undervalued stocks in the Asian market.

Simplywall

TIANQI LITHIUM

Asian Value Stock Picks For Intrinsic Valuation Estimates January 2026

SSNGY

As of 2026, Asian markets are witnessing mixed performances, prompting investors to seek undervalued stocks. Notable mentions include Xi'an International Medical Investment, Xiamen Amoytop Biotech, and Sichuan Kelun-Biotech, all estimated to be significantly below their intrinsic values, with discounts ranging from 48.5% to 49.7%. Samsung Electronics and Wuhan Guide Infrared are also highlighted, trading below their fair values with projected strong earnings growth. These insights suggest potential investment opportunities in the Asian market as companies show promising financial forecasts and growth potential.

Samsung Electronics 

3 Asian Stocks Estimated To Be 35.9% To 49.2% Below Intrinsic Value

600166

As of January 2026, Asian markets are optimistic about AI but cautious about economic growth, particularly in China and Japan. Investors are encouraged to explore undervalued stocks, with notable mentions including CLASSYS, Beiqi Foton Motor, and Xiamen Amoytop Biotech, all trading significantly below their estimated fair values. CLASSYS shows a 42% discount, Beiqi Foton at 34%, and Xiamen Amoytop at 48.5%. These companies exhibit strong earnings growth potential, making them attractive options for investors seeking opportunities in the current market.

FOTON

3 Asian Stocks Estimated To Be Undervalued In January 2026

601567

301589

Asian stocks are estimated to be up to 26% below intrinsic value, presenting growth opportunities for investors. Key undervalued stocks include Xi'an NovaStar Tech, Xiamen Amoytop Biotech, and Ningbo Sanxing Medical Electric, among others. Despite volatility, these stocks show potential for significant earnings growth. The article highlights the importance of identifying undervalued stocks in a complex market environment, offering insights into their financial health and growth forecasts.

SANXING

Novastar

Asian Market Stocks Estimated Up To 26% Below Intrinsic Value

According to the Zhitong Finance APP, AMOYTOP disclosed its third-quarter report for 2025. The company achieved revenue of 2.48 billion yuan in the first three quarters, a year-on-year increase of 26.85%; the net profit attributable to shareholders of the listed company was 666 million yuan, a year-on-year increase of 20.21%; the net profit excluding non-recurring gains and losses was 673 million yuan, a year-on-year increase of 15.91%; the basic earnings per share were 1.64 yuan

Zhitong

AMOYTOP released its performance for the first three quarters, with a net profit attributable to the parent company of 666 million yuan, a year-on-year increase of 20.21%

AMOYTOP announced that its core product Pegasys's supplemental indication marketing authorization application has been approved by the National Medical Products Administration. This product is used for the sustained clearance of HBsAg in adult patients with chronic hepatitis B and is the world's first 40kD polyethylene glycol long-acting interferon α-2b injection, classified as a national Class 1 new drug. Pegasys was launched in 2016, initially for the treatment of adult chronic hepatitis C, and was approved for adult chronic hepatitis B in 2017

AMOYTOP: The application for the marketing authorization of Pegfilgrastim for additional indications has been approved

00522

Asian stock markets are presenting significant opportunities for value investors as they navigate economic shifts. A list of the top 10 undervalued stocks based on cash flows includes companies like Xiamen Amoytop Biotech and Takara Bio, with discounts to fair value ranging from 48.9% to 49.8%. Notable mentions include ASMPT and Newborn Town, both trading below their estimated fair values, indicating potential for growth. Analysts suggest these stocks may capitalize on market inefficiencies, making them attractive for investment.

ASMPT

Asian Value Stocks Offering Estimated Opportunities In September 2025

AMOYTOP released its semi-annual report for 2025, with operating revenue of 1.511 billion yuan, a year-on-year increase of 26.96%; net profit attributable to the parent company was 428 million yuan, a year-on-year increase of 40.60%. The net profit after deducting non-recurring gains and losses was 431 million yuan, a year-on-year increase of 30.68%. The basic earnings per share were 1.05 yuan. The growth in performance was mainly attributed to the popularization of the clinical cure concept for hepatitis B and the increase in patients treated with the core product, Peginterferon

AMOYTOP released its performance for the first half of the year, with a net profit attributable to the parent company of 428 million yuan, an increase of 40.60%

002250

300204

According to statistics, innovative drug concept stocks have performed strongly this year, with an average increase of 27.34%, among which 6 individual stocks have doubled in price. Staidson BioPharm had the highest increase, reaching 292.98%. It is expected that from 2025 to 2026, the net profits of 19 innovative drug concept stocks will continue to grow by more than 20%. Companies such as BeiGene and AMOYTOP have received leveraged funding increases this month

LIANHE TECHNOLOGY

Staidson BioPharm

Sunshine Guojian Pharmaceutical

BETTA PHARMACEUTICALS

Gan & Lee

SDKX

Chemexpress

贝达药业

Institutional consensus predicts that innovative drug concept stocks are expected to continue growing in performance over the next two years

AMOYTOP(688278.SH)